Martek, Numico deal
This article was originally published in The Tan Sheet
Nutritional oil manufacturer Martek Biosciences will exclusively supply infant formula producer Numico with ARA and microbially-derived DHA for its infant formula products under a 15-year deal between the firms, Martek announces Feb. 19. The agreement extends an existing license agreement that has been in place since 1994, but allows Numico to terminate the arrangement as early as January 2012, Martek states. "With this new agreement, more than 70 percent of Martek's business in the infant formula market is subject to multi-year sole source agreements," firm notes...
You may also be interested in...
Sales of life'sDHA to international infant formula manufacturers helped drive nutritional oil developer Martek Biosciences' revenue up 18 percent to a record $82.9 million during its fiscal 2008 first quarter, the firm says
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.